Guideline‑Directed Medical Therapy Sequence in HFrEF
Guideline‑directed medical therapy (GDMT) for HFrEF includes an ACE inhibitor (ACEi), angiotensin‑receptor blocker (ARB), or angiotensin‑receptor–neprilysin inhibitor (ARNI); a beta‑blocker; a mineralocorticoid receptor antagonist (MRA); and a sodium‑glucose cotransporter‑2 inhibitor (SGLT2i) [1][2].
Initial Initiation
- Begin an ACEi, ARB, or ARNI at a low dose within the first clinic visit after diagnosis of HFrEF [1][3].
- Start a beta‑blocker (evidence‑based agents such as carvedilol, metoprolol succinate, or bisoprolol) at a low dose concurrently or within the first two weeks [1][3].
- Add an MRA (spironolactone or eplerenone) once the patient is euvolemic and has tolerated ACEi/ARB/ARNI and beta‑blocker, typically within the first month [1][3].
- Initiate an SGLT2i (dapagliflozin or empagliflozin) as early as possible, without a required titration period, and irrespective of diabetes status [1][3].
Titration Strategy
- Titrate ACEi/ARB/ARNI to the target or maximally tolerated dose before up‑titrating the beta‑blocker, aiming for guideline‑specified targets [1][3].
- After achieving target ACEi/ARB/ARNI dose, up‑titrate the beta‑blocker to the target dose, monitoring heart rate and blood pressure [1][3].
- Once ACEi/ARB/ARNI and beta‑blocker are at target or maximally tolerated doses, titrate the MRA to its target dose, monitoring potassium and renal function [1][3].
- No dose titration is required for SGLT2i beyond the standard initiation dose [1][3].
Substituting or Adding ARNI
- Replace ACEi or ARB with an ARNI (sacubitril/valsartan) after the patient has been on a stable dose of ACEi/ARB for at least 36 hours to reduce the risk of angioedema [1][4].
- Initiate ARNI de novo in ACEi‑naïve patients with symptomatic HFrEF when rapid neuro‑hormonal blockade is desired, using the same low‑dose start and titration schedule as for ACEi [1][4].
- If a patient is already on an ACEi/ARB, transition to ARNI as soon as clinically feasible, provided blood pressure, renal function, and potassium are acceptable [1][4].
Practical Workflow
| Step | Medication class | Timing of start | Target titration sequence |
|---|---|---|---|
| 1 | ACEi/ARB/ARNI | Day 0–7 | Up‑titrate to target before beta‑blocker titration |
| 2 | Beta‑blocker | Day 0–14 (concurrent) | Up‑titrate after ACEi/ARB/ARNI target reached |
| 3 | MRA | ≤30 days, once euvolemic | Up‑titrate after beta‑blocker target reached |
| 4 | SGLT2i | As early as possible, no titration | Maintain standard dose throughout |
Key Points
- All four drug classes are recommended for nearly all patients with HFrEF unless contraindicated [1][2].
- Early initiation of SGLT2i is emphasized because benefits are independent of glycemic status [1][2].
- Transition to ARNI should respect the 36‑hour washout after ACEi and consider patient tolerance [1][4].